[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361466-105":59,"doc-detail-361466-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","spatial-omics-in-high-grade-gliomas-mapping-immunetumor-niches-for-precision-therapy","Spatial Omics in High-Grade Gliomas: Mapping Immune–Tumor Niches for Precision Therapy","","High-grade gliomas (HGGs), especially glioblastoma (GBM), continue to drive extreme mortality despite decades of molecular profiling and therapeutic development. Treatment failure stems in large part from spatial biology: malignant cell states, immune suppression, metabolic stress, and therapy resistance are organized into anatomically and functionally distinct niches. Spatial omics enables high-dimensional mapping of gene expression, immune architecture, and metabolic activity directly within intact tumor tissue, revealing region-specific determinants of resistance, recurrence, and immunotherapy exclusion. This review synthesizes spatial transcriptomic and immune-profiling evidence to define tumor–immune niches and bottlenecks that constrain precision therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/spatial-omics-in-high-grade-gliomas-mapping-immunetumor-niches-for-precision-therapy/361466/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/spatial-omics-in-high-grade-gliomas-mapping-immunetumor-niches-for-precision-therapy/361466.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do high-grade gliomas often fail to respond to therapy?","Question",{"text":113,"@type":114},"A major driver is spatial biology: malignant states, immune suppression, metabolic stress, and resistance programs occupy distinct anatomical and functional niches, limiting uniform treatment effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does spatial omics improve understanding of glioblastoma?",{"text":118,"@type":114},"Spatial omics maps gene expression, protein signaling, immune architecture, and metabolic activity within intact tumor tissue, showing how transcriptional states and immune features localize to specific regions.",{"name":120,"@type":111,"acceptedAnswer":121},"What does the review say about immune exclusion and immunotherapy failure?",{"text":122,"@type":114},"It links immunotherapy failure to immune exclusion mechanisms dominated by myeloid immune features, where location within tumor niches influences clinical outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},361466,1790491051,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nSpatial Omics in High-Grade Gliomas: Mapping Immune–Tumor Niches for Precision Therapy  \nSaniyah Shaikh1 | Thaabit Raziq1 | Sulaf B. Alfares1 | Touleen T. Raslan1 | Ismail A. Abdullah1 | Itika Arora1,2 | Shamsa Saleh1 | Mohammed Imran Khan1,3  | Ahmed Yaqinuddin1  \n1College of Medicine, Alfaisal University, Riyadh, Saudi Arabia | 2Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, UAE | 3King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia  \nCorrespondence: Ahmed Yaqinuddin ([ayaqinuddin@alfaisal.edu](ayaqinuddin@alfaisal.edu))  \nReceived: 7 February 2026 | Revised: 25 May 2026 | Accepted: 25 August 2026  \nKeywords: glioblastoma | high grade glioma | spatial biology | spatial omics  \nABSTRACT  \nHigh-grade gliomas (HGGs), particularly glioblastoma (GBM), remain among the most lethal human cancers despite decades of molecular profiling and therapeutic innovation. A primary reason for treatment failure is that HGG biology is spatial: malignant cell states, immune suppression, metabolic stress, and therapeutic resistance are organized into distinct anatomical and functional niches. Spatial omics technologies now enable high-dimensional mapping of gene expression, protein signaling, immune architecture, and metabolic activity within intact tumor tissue. These approaches reveal how proneural and mesenchymal transcriptional states coexist yet localize to distinct regions, alongside hypoxic, invasive, and stem-enriched niches. Spatial analyses show that key clinical determinants, including O6-methylguanine-DNA methyltransferase (MGMT)-associated temozolomide resistance, radiotherapy tolerance in hypoxic regions, and immunotherapy failure driven by myeloid-dominated immune exclusion, are influenced not only by molecular programs but also by cellular location. Beyond biological insight, spatial omicsis reshaping clinical paradigms by enabling region-specific patient stratification, early assessment of treatment response, and identification of therapy-resistant reservoirs that seed recurrence. Prior bulk and single-cell studies defined HGG cell states and pathways but often treated resistance as tumor-wide. This review presents a spatially explicit framework that synthesizes spatial transcriptomic and immune-profiling studies to identify tumor–immune niches and spatial bottlenecks that drive therapeutic failure and recurrence.  \n1 | Clinical and Biological Context of High-Grade Glioma (HGG)  \nHigh-grade gliomas (HGGs), particularly glioblastoma (GBM, WHO grade 4), are the most common malignant primary brain tumors in adults and remain a leading cause of cancerrelated mortality in children and young adults. These tumors are aggressive, diffusely infiltrative, and universally fatal despite decades of molecular characterization and therapeutic innovation [1–3] . At the biological level, HGGs exhibit profound intratumoral heterogeneity across histologic, cellular, and molecular dimensions, encompassing diverse tumor cell  \nstates, stromal components, and immune infiltrates [1, 4, 5] . Genomic and transcriptomic profiling has revealed frequent alterations in oncogenic signaling pathways, including RAS/ RAF/MAPK, PI3K/AKT/mTOR, and cell cycle regulators [1, 6] . The current standard of care, maximal safe surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide (RT/TMZ), confers only modest survival benefit, with median survival limited to 12–15 months and 5-year survival rates below 10%[2, 3, 7, 8] . Although this review focuses primarily on GBM as the most extensively characterized and clinically dominant WHO grade 4 glioma, several spatial, immune, and therapeutic resistance mechanisms  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for c","cbCaiknG25BtDZcH","https://ap.wps.com/l/cbCaiknG25BtDZcH","pdf",1266506,16,"English","# Clinical and Biological Context of High-Grade Glioma (HGG)\n## Spatial Organization of Tumor Cell States and Microenvironmental Niches","[{\"question\":\"Why do high-grade gliomas often fail to respond to therapy?\",\"answer\":\"A major driver is spatial biology: malignant states, immune suppression, metabolic stress, and resistance programs occupy distinct anatomical and functional niches, limiting uniform treatment effectiveness.\"},{\"question\":\"How does spatial omics improve understanding of glioblastoma?\",\"answer\":\"Spatial omics maps gene expression, protein signaling, immune architecture, and metabolic activity within intact tumor tissue, showing how transcriptional states and immune features localize to specific regions.\"},{\"question\":\"What does the review say about immune exclusion and immunotherapy failure?\",\"answer\":\"It links immunotherapy failure to immune exclusion mechanisms dominated by myeloid immune features, where location within tumor niches influences clinical outcomes.\"}]","Spatial Omics in High-Grade Gliomas: Mapping Immune–Tumor Niches for Precision Therapy | PDF",1790144427,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/987eeae51bd23199ec3fb919252fe466.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0b55cb6ee1b460434104c84e225aad6.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/673f1e6254705e1157f8a5d238c2ffac.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a8e0ddf84e48c035f75fa7654d93908.webp",980,1287]